Blue Clay Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Blue Clay Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$1.75M	Buy	27,451 +1,603	+6%	+$118K	1.97%	9
2016 Q2	$1.92M	Sell	25,848 -2,405	-9%	-$178K	2.24%	7
2016 Q1	$1.89M	Sell	28,253 -4,088	-13%	-$248K	1.78%	13
2015 Q4	$2.19M	Sell	32,341 -3,206	-9%	-$198K	1.81%	8
2015 Q3	$1.9M	Sell	35,547 -5,610	-14%	-$340K	1.51%	17
2015 Q2	$2.59M	Sell	41,157 -17,633	-30%	-$962K	1.47%	11
2015 Q1	$2.83M	Sell	58,790 -7,895	-12%	-$302K	1.48%	12
2014 Q4	$2.21M	Buy	+66,685	New	+$2.17M	1.62%	10

Other funds holding LGND

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Blue Clay Capital Management's LGND Position: Q3 2016 in Review

Blue Clay Capital Management increased its Ligand Pharmaceuticals (LGND) stake by 6.2% in Q3 2016, buying an estimated $118K and bringing the position to 27,451 shares worth $1.75M. The position accounts for 1.97% of the portfolio, ranked #9.

Blue Clay Capital Management first reported a position in LGND in Q4 2014 and has held it in 8 quarters since. The position peaked at $2.83M in Q1 2015. 259 funds tracked by Wall St. Rank hold LGND as of Q3 2016.

Blue Clay Capital Management held 27,451 shares of Ligand Pharmaceuticals worth $1.75M as of Q3 2016.
Blue Clay Capital Management bought 1,603 Ligand Pharmaceuticals shares in Q3 2016, an estimated $118K.
Ligand Pharmaceuticals made up 1.97% of Blue Clay Capital Management's portfolio in Q3 2016, its #9 holding.
Blue Clay Capital Management first reported a position in Ligand Pharmaceuticals in Q4 2014 and has held it in 8 quarters since.
Blue Clay Capital Management's Ligand Pharmaceuticals position peaked at $2.83M in Q1 2015.
259 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2016.

Based on Blue Clay Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.